Table 3. Interaction Effect between Medications and Comorbidities on Risk of MNLIHD.

Variable		OR(95% CI) †	P value &
Amiodarone	Comorbidity ‡		<.001
No	No	As a reference
No	Yes	12.6 (11.3, 14.1)***
Yes	No	2.43 (1.92, 3.06)***
Yes	Yes	18.0 (15.7, 20.5)***
Amiodarone	HBV		0.30
No	No	As a reference
No	Yes	14.0(12.7, 15.3)***
Yes	No	1.48(1.36, 1.61)***
Yes	Yes	18.6(14.4, 24.0)***
Amiodarone	HCV		0.02
No	No	As a reference
No	Yes	23.6(21.4, 26.0)***
Yes	No	1.52(1.39, 1.66)***
Yes	Yes	25.9(20.1, 33.5)***
Mexiletine	Comorbidity ‡		.29
No	No	As a reference
No	Yes	11.3 (10.2, 12.9)***
Yes	No	0.88 (0.58, 1.32)
Yes	Yes	12.1 (10.5, 13.9)***
Propafenone	Comorbidity ‡		.93
No	No	As a reference
No	Yes	11.4 (10.4, 12.7)***
Yes	No	1.18 (0.82, 1.70)
Yes	Yes	13.5 (11.7, 15.6)***
Quinidine	Comorbidity ‡		.72
No	No	As a reference
No	Yes	11.4 (10.4, 12.6)***
Yes	No	1.96 (0.69, 5.62)
Yes	Yes	17.9 (12.9, 25.0)***
Procainamide	Comorbidity ‡		.48
No	No	As a reference
No	Yes	11.4 (10.3, 12.6)***
Yes	No	0.62 (0.15, 2.55)
Yes	Yes	12.2 (8.43, 17.6)***

^†Adjusted for statins, anti-diabetics, and NSAIDS.

^& P value for interaction.

^‡Patients with any of the comorbidities (diabetes, chronic liver disease, cirrhosis, HBV infection, HCV infection, and alcoholism) were classified as the comorbidity group.